SEC Form 4 · accession 0001562180-18-003130
ARRAY BIOPHARMA INC · ARRY
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
Reporting owner
Andrew R Robbins
Officer — COO
Period of report
Jun 27, 2018
Accepted (ET)
Jun 29, 2018 · 4:22 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001100412
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | Jun 27, 2018 | M | 32,068 | $0.00 | A | 191,535 | D | |
| Common StockF2 | Jun 27, 2018 | F | 14,104 | $18.50 | D | 177,431 | D | |
| Common StockF4 | Jun 27, 2018 | S | 17,964 | $17.74 | D | 159,467 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Restricted Stock UnitsF5 | $0.00 | Jun 27, 2018 | M | 32,068 | D | — | Aug 18, 2018 | Common Stock | 32,068 | 0 | D |
Explanation of responses
- F1Represents shares released on vesting of Restricted Stock Units ("RSUs") granted to the reporting person on August 18, 2014. The grant of these RSUs was previously reported on Table II.
- F2Represents shares withheld to satisfy tax withholding obligations of the reporting person.
- F3These trades were made pursuant to a Rule 10b5-1 trading plan.
- F4The price reported for these shares is the weighted average sale price of transactions made at prices from $17.60 to $17.84. Details of actual prices for shares sold are available from the Issuer upon request.
- F5RSUs representing 32,068 shares of common stock vested upon the achievement of a second milestone relating to the return of rights to binimetinib to the Issuer on or prior to the fourth anniversary of the grant date, subject to continued service with the Issuer as of the vesting date.